Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.21.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jul. 31, 2021
Jul. 31, 2020
Cash flow from operating activities:    
Net (loss) income $ (47,944) $ (8,198)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization expense 3,451 2,877
Bad debt expense (226) 286
Stock-based compensation expense, net of amounts capitalized 25,532 9,407
Non-cash interest paid in kind and discount amortization 3,267 1,517
Deferred income taxes 1 87
Other noncash items, net (999) (15)
Changes in operating assets and liabilities:    
Accounts receivable 11,810 29,661
Prepaid expenses and other current assets 1,673 18,243
Other noncurrent assets (7,151) 3,437
Accounts payable (6,751) (2,173)
Accrued expenses and other current liabilities (2,326) (14,474)
Deferred revenue 2,956 (17,240)
Other liabilities (154) 34
Net cash (used in) provided by operating activities (16,861) 23,449
Cash flow from investing activities:    
Purchases of marketable securities (61,758) 0
Sales of marketable securities 56,652 0
Maturities of marketable securities 101,860 0
Purchases of property and equipment (3,862) (1,586)
Capitalized internal-use software (2,481) (1,546)
Net cash provided by (used in) investing activities 90,411 (3,132)
Cash flow from financing activities:    
Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts, commissions and other offering costs 276,001 0
Proceeds from senior subordinated secured convertible notes 0 73,425
Proceeds from short-term borrowings 0 49,973
Repayments of short term borrowings 0 (49,973)
Payments of debt and equity issuance costs 0 (160)
Proceeds from issuance of common stock upon exercise of stock options 16,659 1,357
Net cash provided by financing activities 292,660 74,622
Effect of exchange rate fluctuations on cash and cash equivalents (257) (83)
Net change in cash and cash equivalents 365,953 94,856
Cash and cash equivalents at beginning of period 68,037 10,470
Cash and cash equivalents at end of period 433,990 105,326
Supplemental disclosure of cash flow information    
Cash paid for income taxes 1,564 1,290
Cash paid for interest 0 319
Supplemental disclosure for noncash investing and financing    
Conversion of redeemable preferred stock to Class B common stock 424,992 0
Conversion of senior subordinated secured convertible notes to Class B common stock 82,114 0
Net exercise of common stock warrants 18 0
Stock-based compensation expense capitalized in internal-use software 233 0
Accrued purchases of property and equipment 181 149
Common stock issued in exchange for other noncash assets 0 5,000
Deferred offering costs included in accounts payable and accrued liabilities $ 47 $ 0